George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

4D Pharma Files US Registration Statement For ADR Programme

Thu, 26th Nov 2020 10:53

(Alliance News) - 4D Pharma PLC on Thursday said it has filed a registration statement in the US and expects to launch a new American depositary receipt programme in connection with its proposed Longevity Acquisition Corp merger.

Shares in 4D Pharma were up 3.6% at 93.40 pence in London in morning trading.

The Leeds-based pharmaceutical company announced plans for its merger with NASDAQ-listed special-purpose acquisition company Longevity Acquisition Corp back in October.

The SPAC's shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each, GBP144.5 million altogether.

4D Pharma will launch its ADR programme and apply to admit its ADSs for trading on NASDAQ. These will then, if 4D Pharma shareholders give approval, be offered to Longevity shareholders as consideration under the terms of the merger.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Apr 2016 08:25

4D Pharma Buys Assets From Partner In Deal Worth Up To EUR6 Million (ALLISS)

Read more
31 Mar 2016 08:47

4d Pharma Annual Loss Widens On Higher Research Spending

Read more
26 Feb 2016 15:49

Good news, and some not-so-good news from 4D pharma

(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio

Read more
26 Feb 2016 09:16

4D Pharma Quality Concerns Delay Thetanix Dosing, Recruits For Blautic

Read more
10 Feb 2016 15:12

4D Pharma expands research with Tuscana acquisition

(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi

Read more
10 Feb 2016 08:57

4D Pharma Acquires University Start-Up Company Tucana Health (ALLISS)

Read more
19 Jan 2016 07:51

4d Pharma Gets Good Early Results From Blautix Trials

Read more
8 Dec 2015 07:46

4d Pharma Raises GBP30.0 Million For Business Development (ALLISS)

Read more
26 Nov 2015 10:10

4D Pharma Finds Live Biotherapeutic For Breast, Lung Cancer Treatment

Read more
11 Nov 2015 11:15

4D Pharma Gets Approval For Phase 1 Study Of Crohn's Disease Drug

Read more
29 Sep 2015 12:08

4D Pharma Progresses Pipeline As It Swings To Loss In First Half

Read more
21 Aug 2015 06:49

4D Pharma Commences Dosing In Irritable Bowel Syndrome Clinical Trial

Read more
11 Aug 2015 14:15

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta

Read more
7 Aug 2015 06:31

4D Pharma Agrees EUR4.8 Million Collaboration With APC Microbiome

Read more
16 Jun 2015 08:33

4D Pharma posts "exciting" development results from MicroRx

Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx. The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis. The group also identified

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.